Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Rhea-AI Summary
Ardelyx (ARDX) has scheduled a conference call for Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss its full year and fourth quarter 2024 financial results and provide a business update. Participants can join via phone by dialing (877) 346-6112 (domestic) or (848) 280-6350 (international). The call will also be webcast live on the company's website under the Investors section, with a replay available for 30 days following the call.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARDX declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call scheduled for 8:00 a.m. Eastern Time
WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024.
To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Ardelyx (ARDX) report Q4 and full-year 2024 earnings?
How can investors join the ARDX Q4 2024 earnings call?
How long will the ARDX Q4 2024 earnings call webcast be available for replay?
Where can I access the webcast for ARDX's Q4 2024 earnings call?
